Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections

References

• Gould IM. Antibiotic resistance: the perfect storm. Int J Antimicrob Agents 2009; 34:Suppl 3 S2 - 5; http://dx.doi.org/10.1016/S0924-8579(09)70549-7; PMID: 19596110
   PubMed Web of Science ®Google Scholar
• Taubes G. The bacteria fight back. Science 2008; 321:356 - 61; http://dx.doi.org/10.1126/science.321.5887.356; PMID: 18635788
   PubMed Web of Science ®Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42:Suppl 2 S82 - 9; http://dx.doi.org/10.1086/499406; PMID: 16355321
   PubMed Web of Science ®Google Scholar
• Antibiotic Resistance Threats in the United States. Atlanta (GA): Centers for Disease Control: 2013.
   Google Scholar
• Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong SL, Donovan DM. Endolysins as Antimicrobials. In: Lobocka M, Szybalski WT, eds. Advances in Virus Research, Vol 83: Bacteriophages, Pt B, 2012:299-365.
   Google Scholar
• Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 2008; 104:1 - 13; PMID: 18171378
   PubMed Web of Science ®Google Scholar
• Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 2013; 62:1506 - 16; http://dx.doi.org/10.1099/jmm.0.061028-0; PMID: 23813275
   PubMed Web of Science ®Google Scholar
• Koch AL. Bacterial wall as target for attack: past, present, and future research. Clin Microbiol Rev 2003; 16:673 - 87; http://dx.doi.org/10.1128/CMR.16.4.673-687.2003; PMID: 14557293
   PubMed Web of Science ®Google Scholar
• Yount NY, Yeaman MR. Peptide antimicrobials: cell wall as a bacterial target. Ann N Y Acad Sci 2013; 1277:127 - 38; http://dx.doi.org/10.1111/nyas.12005; PMID: 23302022
   PubMed Web of Science ®Google Scholar
• Bhavsar T, Liu M, Hardej D, Liu X, Cantor J. Aerosolized recombinant human lysozyme ameliorates Pseudomonas aeruginosa-induced pneumonia in hamsters. Exp Lung Res 2010; 36:94 - 100; http://dx.doi.org/10.3109/01902140903154608; PMID: 20205599
   PubMed Web of Science ®Google Scholar
• Bhavsar T, Liu M, Liu X, Cantor J. Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia. Exp Lung Res 2011; 37:536 - 41; http://dx.doi.org/10.3109/01902148.2011.609578; PMID: 21967196
   PubMed Web of Science ®Google Scholar
• Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci 2010; 35:127 - 60; http://dx.doi.org/10.1007/s12038-010-0015-5; PMID: 20413917
   PubMed Web of Science ®Google Scholar
• Cole AM, Liao H-I, Stuchlik O, Tilan J, Pohl J, Ganz T. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002; 169:6985 - 91; PMID: 12471133
   PubMed Web of Science ®Google Scholar
• Ibrahim HR, Matsuzaki T, Aoki T. Genetic evidence that antibacterial activity of lysozyme is independent of its catalytic function. FEBS Lett 2001; 506:27 - 32; http://dx.doi.org/10.1016/S0014-5793(01)02872-1; PMID: 11591365
   PubMed Web of Science ®Google Scholar
• Masschalck B, Michiels CW. Antimicrobial properties of lysozyme in relation to foodborne vegetative bacteria. Crit Rev Microbiol 2003; 29:191 - 214; http://dx.doi.org/10.1080/713610448; PMID: 14582617
   PubMed Web of Science ®Google Scholar
• Nash JA, Ballard TNS, Weaver TE, Akinbi HT. The peptidoglycan-degrading property of lysozyme is not required for bactericidal activity in vivo. J Immunol 2006; 177:519 - 26; PMID: 16785549
   PubMed Web of Science ®Google Scholar
• Scanlon TC, Teneback CC, Gill A, Bement JL, Weiner JA, Lamppa JW, Leclair LW, Griswold KE. Enhanced antimicrobial activity of engineered human lysozyme. ACS Chem Biol 2010; 5:809 - 18; http://dx.doi.org/10.1021/cb1001119; PMID: 20604527
   PubMed Web of Science ®Google Scholar
• Scanlon TC, Gray EC, Griswold KE. Quantifying and resolving multiple vector transformants in S. cerevisiae plasmid libraries. BMC Biotechnol 2009; 9:95; http://dx.doi.org/10.1186/1472-6750-9-95; PMID: 19930565
   PubMed Web of Science ®Google Scholar
• Gill A, Scanlon TC, Osipovitch DC, Madden DR, Griswold KE. Crystal structure of a charge engineered human lysozyme having enhanced bactericidal activity. PLoS One 2011; 6:e16788; http://dx.doi.org/10.1371/journal.pone.0016788; PMID: 21408218
   PubMedGoogle Scholar
• Teneback CC, Scanlon TC, Wargo MJ, Bement JL, Griswold KE, Leclair LW. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother 2013; 57:5559 - 64; http://dx.doi.org/10.1128/AAC.00500-13; PMID: 23979752
   PubMed Web of Science ®Google Scholar
• Sievert DMP, Ricks P, Edwards JRMS, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1 - 14; http://dx.doi.org/10.1086/668770; PMID: 23221186
   PubMed Web of Science ®Google Scholar
• Ohman DE, Chakrabarty AM. Utilization of human respiratory secretions by mucoid Pseudomonas aeruginosa of cystic fibrosis origin. Infect Immun 1982; 37:662 - 9; PMID: 6811437
   PubMed Web of Science ®Google Scholar
• Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. [CMLS] Cell Mol Life Sci 2007; 64:922 - 33; http://dx.doi.org/10.1007/s00018-007-6475-6; PMID: 17310278
   PubMed Web of Science ®Google Scholar
• Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55:27 - 55; http://dx.doi.org/10.1124/pr.55.1.2; PMID: 12615953
   PubMed Web of Science ®Google Scholar
• Haney EF, Hancock REW. Peptide design for antimicrobial and immunomodulatory applications. Biopolymers 2013; 100:572 - 83; http://dx.doi.org/10.1002/bip.22250; PMID: 23553602
   PubMed Web of Science ®Google Scholar
• Hilpert K, Elliott M, Jenssen H, Kindrachuk J, Fjell CD, Körner J, Winkler DFH, Weaver LL, Henklein P, Ulrich AS, et al. Screening and characterization of surface-tethered cationic peptides for antimicrobial activity. Chem Biol 2009; 16:58 - 69; http://dx.doi.org/10.1016/j.chembiol.2008.11.006; PMID: 19171306
   PubMed Web of Science ®Google Scholar
• Purdy Drew KR, Sanders LK, Culumber ZW, Zribi O, Wong GCL. Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes. J Am Chem Soc 2009; 131:486 - 93; http://dx.doi.org/10.1021/ja803925n; PMID: 19072156
   PubMed Web of Science ®Google Scholar
• Ibrahim HR. New drug-targeting strategy from beneath the shell of egg. Expert Opin Drug Deliv 2010; 7:1145 - 58; http://dx.doi.org/10.1517/17425247.2010.515208; PMID: 20836624
   PubMed Web of Science ®Google Scholar
• Higo J, Nakasako M. Hydration structure of human lysozyme investigated by molecular dynamics simulation and cryogenic X-ray crystal structure analyses: on the correlation between crystal water sites, solvent density, and solvent dipole. J Comput Chem 2002; 23:1323 - 36; http://dx.doi.org/10.1002/jcc.10100; PMID: 12214315
   PubMed Web of Science ®Google Scholar